Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
25 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Regulation FD Disclosure
3 Apr 24
8-K
Entry into a Material Definitive Agreement
13 Mar 24
8-K
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
4 Mar 24
8-K
Other Events
12 Feb 24
8-K
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
29 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
6 Nov 23
8-K
Departure of Directors or Certain Officers
3 Oct 23
8-K
Skye Bioscience Reverse Stock Split to be Effective on September 8th
7 Sep 23
8-K/A
Departure of Directors or Certain Officers
1 Sep 23
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
24 Apr 24
424B3
Prospectus supplement
10 Apr 24
8-A12B
Registration of securities on exchange
10 Apr 24
S-1/A
IPO registration (amended)
4 Apr 24
S-1
IPO registration
27 Mar 24
D
$40.00 mm in equity, sold $40.00 mm, 13 investors
26 Mar 24
D
$49.99 mm in equity / options, sold $49.99 mm, 11 investors
12 Feb 24
S-8
Registration of securities for employees
21 Dec 23
D
$62.25 mm in equity / debt / options / securities to be acquired, sold $62.25 mm, 12 investors
29 Aug 23
424B3
Prospectus supplement
10 Nov 21
Proxies
DEF 14C
Information statement
16 Oct 23
PRE 14C
Preliminary information
3 Oct 23
DEFA14A
Additional proxy soliciting materials
1 Sep 22
DEFM14A
Proxy related to merger
31 Aug 22
PREM14A
Preliminary proxy related to merger
15 Aug 22
DEF 14A
Definitive proxy
22 Dec 20
PRE 14A
Preliminary proxy
11 Dec 20
DEF 14C
Information statement
30 Oct 19
DEF 14C
Information statement
4 Mar 19
PRE 14C
Preliminary information
20 Feb 19
Other
EFFECT
Notice of effectiveness
11 Apr 24
CERT
Certification of approval for exchange listing
10 Apr 24
EFFECT
Notice of effectiveness
10 Aug 21
CORRESP
Correspondence with SEC
5 Aug 21
UPLOAD
Letter from SEC
4 Aug 21
EFFECT
Notice of effectiveness
3 Aug 20
CORRESP
Correspondence with SEC
29 Jul 20
UPLOAD
Letter from SEC
16 Jul 20
EFFECT
Notice of effectiveness
18 Mar 20
EFFECT
Notice of effectiveness
14 Feb 20
Ownership